Skip to content
Medical Health Aged Care

Emerging field of circadian medicine gets a boost with new global association

Monash University 2 mins read

World-leading experts in the emerging field of circadian medicine are proud to announce a new global association to further the science of sleep and other circadian rhythms, and take those findings into clinical practice.

The International Association of Circadian Health Clinics (IACHC) will bring together researchers and clinicians across the globe - including the USA, Asia, Europe and Australia - to develop evidence-based, personalised patient care centred around the circadian timing system.

Monash University Professor of Sleep and Circadian Medicine, Shantha Rajaratnam, said the association was a major step in advancing circadian-informed diagnosis and treatment for many disorders.

“Circadian processes affect every system in the body, and have an enormous impact on sleep, metabolism, mental health and progression of diseases such as cancer,” he said. “This association will advance and coordinate the emerging field of clinical circadian medicine to achieve significant impact on healthcare and benefit to patients.”

Researchers from Monash University’s Turner Institute for Brain and Mental Health and School of Psychological Sciences have formed a working group to steer the association’s vision, with colleagues at Harvard Medical School (including Brigham and Women’s Hospital and Massachusetts General Hospital), Northwestern University, University of Colorado, Brown University, Canada’s McGill University, the Psychiatric Hospital of the University of Basel in Switzerland, the University of Bergen in Norway, and Charité Universitätsmedizin Berlin.

The association will offer members:


Research and innovation: research initiatives, encourage innovation, and drive technological advancements in circadian medicine.

Educational resources: programs, webinars, workshops, and conferences to foster continuous learning and professional development.

Advocacy and representation: a unified voice for circadian health professionals and clinicians, promoting industry best practices, and influencing policy decisions.

Networking opportunities: access to a diverse community of research and clinical professionals, to forge valuable connections, exchange ideas, and build partnerships.

Membership of the International Association of Circadian Health Clinics is open to professionals, organisations, and stakeholders across the sleep and circadian medicine field. Visit https://circadianhealthclinics.com/ 

For media enquiries please contact:

Monash University

Cheryl Critchley - Communications Manager (medical)
E: [email protected] 

T: +61 (0) 418 312 596

For more Monash media stories, visit our news and events site  


For general media enquiries please contact:
Monash Media
E: [email protected]
T: +61 (0) 3 9903 4840

 

***ENDS***

 

More from this category

  • Medical Health Aged Care
  • 10/03/2026
  • 20:11
Ferring Pharmaceuticals

For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025

Ferring’s total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur® Continued ramp-up in…

  • Contains:
  • Legal, Medical Health Aged Care
  • 10/03/2026
  • 17:30
Maddens Lawyers

Thousands register to participate in the Dr Lanzer Class Action

Patients who underwent cosmetic surgery at the Lanzer Clinics have until 4.00pm Friday 10 April to register or opt out of a class action set for trial in the Supreme Court of Victoria in September. The class action alleges that Dr Daniel Lanzer and his colleagues Dr Daniel Aronov, Dr Ryan Wells, Dr Alieza Fallahi, Dr George Wong, and Dr Daniel Darbyshire engaged in misleading and negligent practices while performing cosmetic surgeries, with many former patients left with injuries and ongoing pain. Psychologist Candice Wainstein, who is the wife of Dr Aronov, is also a defendant. Maddens Lawyers principal Kathryn…

  • Contains:
  • Medical Health Aged Care
  • 10/03/2026
  • 16:28
Phebra

Phebra launches Rapiblyk® in Australian healthcare settings

Australian Pharmaceutical company Phebra (‘Company’) has announced the launch of Rapiblyk® (landiolol hydrochloride), an ultra‑short‑acting, cardio-selective receptor antagonist, indicated for rapid control of ventricular rate in patients with severe, acute cardiac arrhythmias (irregular rapid heart rate) in critical care settings. Clinical studies have demonstrated that Rapiblyk® enables safe, effective heart rate control with limited impact on blood pressure and inotropy (heart contractility). Rapiblyk® has a very short half life delivering a fast onset and offset of action. This provides clinicians with a higher level of precision in life-threatening situations. Phebra CEO Andre Vlok highlighted how Rapiblyk® strengthens the company's critical…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.